Aripiprazole (Abilify®) as an Adjunctive Treatment for Inadequate Response in Major Depressive Disorder
Status:
Completed
Trial end date:
2019-02-01
Target enrollment:
Participant gender:
Summary
The investigators hypothesized that combined pharmacotherapy using adjunctive aripiprazole of
standard antidepressants would be associated with improved depression response in Major
depressive disorder, especially in Quality of life.
The investigators compare the mean changes in the quality of life between before add-on and 8
weeks treatment of aripiprazole and between before add-on and 6 weeks treatment of
aripiprazole.